moxifloxacin has been researched along with macitentan in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (macitentan) | Trials (macitentan) | Recent Studies (post-2010) (macitentan) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 233 | 34 | 214 |
| Protein | Taxonomy | moxifloxacin (IC50) | macitentan (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | 0.391 | |
| Endothelin receptor type B | Homo sapiens (human) | 0.5897 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0015 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dingemanse, J; Lindegger, N; Reseski, K; Sidharta, PN | 1 |
1 trial(s) available for moxifloxacin and macitentan
| Article | Year |
|---|---|
Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects.
Topics: Adult; Arrhythmias, Cardiac; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Endothelin Receptor Antagonists; Female; Fluoroquinolones; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Pyrimidines; Sulfonamides; Young Adult | 2014 |